Trial Profile
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 31 Jan 2020 Status changed from suspended to completed.
- 21 Aug 2019 Status changed from recruiting to suspended.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.